Epitome Biosystems Names Edward Machuga Vice President Sales and Marketing

Business Wire, Sept 12, 2007

WALTHAM, Mass. -- Epitome Biosystems, a leader in quantitative protein measurement solutions, announced today the appointment of Edward Machuga to Vice President, Sales and Marketing. In this newly created position, Mr. Machuga will be responsible for all commercial activities, including sales of the newly launched Ti-Tyr[TM] Profiling Chip and Q-SONAR[TM] Discovery Service, as well as other products that will emerge from Epitome's pipeline. Mr. Machuga is a seasoned healthcare sales and marketing executive, most recently directing and implementing commercial activities at GE Healthcare's Research Sciences group.

"The addition of Ed to our team highlights our commitment to a product-driven strategy and to continue establishing a strong market presence for our products and services," said Neal Gordon, Ph.D., President, Epitome Biosystems. "With the recent launch of our Ti-Tyr[TM] Chip and Q-SONAR[TM] Service, Epitome is delivering innovative solutions to customers that alleviate key bottlenecks in drug discovery and clinical research. We are thrilled to attract an individual with Ed's exceptional track record in selling and marketing products and services to pharma, biotech and academic customers."

Mr. Machuga's career spans more than 20 years of sales and marketing experience in the life science research market. Prior to GE Healthcare, Mr. Machuga served pivotal roles as VP Sales and Marketing and VP Sales at TekCel and Argonaut Technologies, respectively, where he was responsible for establishing the commercial infrastructure and growing sales. Previously, he held sales and sales management roles during his tenure at PerSeptive Biosystems/PE Biosystems, now part of the Applied Biosystems group of Applera Corporation. In addition to a strong business, sales and marketing background, Mr. Machuga has a Bachelors degree in Biochemistry from The University of Connecticut.

"This is an exciting time to join Epitome and help drive the commercial adoption of its revolutionary products and services," Mr. Machuga commented. "In less than two years, the Company has developed and launched unique, research products with more in the pipeline that will enable new research approaches for targeted drugs and diagnostics."

Epitome's proprietary EpiTag[TM] and Q-SONAR[TM] technologies provide quantitative measurements of biological function across cell signaling networks. The EpiTag[TM] platform enables reliable and cost-effective development of multiplex assays for the quantitative measurement of proteins or phosphorylation states of proteins. The flexible technology is available in antibody array products for broad phosphorylation profiling, such as the Ti-Tyr[TM] Chip and in multiplex assay products for highly quantitative protein measurements. Epitome's Q-SONAR[TM] Discovery Service is a mass spectrometry approach for examining dynamic tyrosine phosphorylation events on multiple pathway proteins on a global scale. Q-SONAR[TM] enables the identification of phosphopeptide 'signatures' or 'fingerprints' that provide a real-time readout of a cell's activation state.

About Epitome Biosystems

Epitome Biosystems is applying its protein measurement systems to increase the productivity of drug discovery and development and improve the understanding of patient variability and disease. The Company's EpiTag[TM] technology delivers highly specific, quantitative, multiplexed measurements of any protein or proteins in a user-friendly format. The Q-SONAR[TM] mass spectrometry-based biomarker discovery service generates quantitative phosphorylation profiles to elucidate cellular network responses. Epitome's technology is validated, scaleable and can be applied broadly to assessing protein functional states or activities, including phosphorylation. For more information, visit www.epitomebiosystems.com.